ANIXA BIOSCIENCES INC (NASDAQ: ANIX)

ANIXA BIOSCIENCES INC

NASDAQ: ANIX (Anixa Biosciences, Inc.)

Last update: 25 Dec, 2025, 7:27PM

3.42

0.12 (3.64%)

Add to watchlist

Previous Close	3.30
Open	3.31
Volume	74,693
Avg. Volume (3M)	320,617
Market Cap	112,575,856

Price / Book

6.19

52 Weeks Range	2.07 (-39%) — 5.46 (59%)
Earnings Date	9 Jan 2026

Market Trend

		Short Term	Medium Term
Industry	Biotechnology (US)	Bullish	Mixed
	Biotechnology (Global)	Bullish	Mixed
Stock	Anixa Biosciences, Inc.	Bullish	Bullish

AIStockmoo Score

1.1

Analyst Consensus	3.5
Insider Activity	NA
Price Volatility	-1.0
Technical Moving Averages	2.5
Technical Oscillators	-0.5
Average	1.13

Similar Stocks

Stock	Market Cap	DY	P/E (TTM)	P/B
ANIX	113 M	-	-	6.19
IONS	13 B	-	-	20.95
VRNA	9 B	-	-	33.01
RYTM	8 B	-	-	47.09
IMVT	5 B	-	-	10.04
SRRK	4 B	-	-	19.02

Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
Sector	Healthcare
Industry	Biotechnology
Investment Style	Small Core
% Held by Insiders	5.32%
% Held by Institutions	17.60%

Ownership

Name	Date	Shares Held
Laird Norton Wetherby Trust Company, Llc	30 Sep 2025	597,235

52 Weeks Range	2.07 (-39%) — 5.46 (59%)
Median	10.00 (192.40%)
Total	1 Buy

Firm	Date	Target Price	Call	Price @ Call
D. Boral Capital	12 Dec 2025	10.00 (192.40%)	Buy	3.58

No data within this time range.

Date	Type	Details
15 Dec 2025	Announcement	Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic
11 Dec 2025	Announcement	Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants
10 Dec 2025	Announcement	Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025
17 Nov 2025	Announcement	Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization
12 Nov 2025	Announcement	Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s
10 Nov 2025	Announcement	Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11, 2025
05 Nov 2025	Announcement	Anixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic
23 Oct 2025	Announcement	Anixa Biosciences to Present at the Spartan Capital Securities Second Annual Investor Conference
20 Oct 2025	Announcement	Anixa Biosciences Announces Issuance of Chinese Patent Covering Breast Cancer Vaccine Technology

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Realized Profit	-
Unrealized Profit	-
Dividend Received 2026	-
Total Profit	-
Avg. Return	-
Quantity (Buy)	-
Avg. Price (Buy)	-
Quantity (Sold)	-
Avg. Price (Sold)	-

No stocks matching your criteria

Total Debt/Equity (MRQ)	1.48%
Current Ratio (MRQ)	8.89
Operating Cash Flow (TTM)	-7.98 M
Levered Free Cash Flow (TTM)	-3.59 M

Return on Assets (TTM)	-39.75%
Return on Equity (TTM)	-65.38%

Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)